121 related articles for article (PubMed ID: 33360511)
21. miR-205 Promotes Apoptosis of Cervical Cancer Cells and Enhances Drug Sensitivity of Cisplatin by Inhibiting YAP1.
Li X; Li Y; Han Y; Dong B; Liu D; Che L; Liu Y; Wang Y
Cancer Biother Radiopharm; 2020 Jun; 35(5):338-344. PubMed ID: 32379984
[No Abstract] [Full Text] [Related]
22. microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1.
Jiang K; Zou H
Bioengineered; 2022 Jan; 13(1):917-929. PubMed ID: 34968160
[TBL] [Abstract][Full Text] [Related]
23. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
Li J; Chen L; Xiong Y; Zheng X; Xie Q; Zhou Q; Shi L; Wu C; Jiang J; Wang H
Cell Physiol Biochem; 2017; 41(3):907-920. PubMed ID: 28222426
[TBL] [Abstract][Full Text] [Related]
24. MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1.
Sun JR; Zhang X; Zhang Y
Cell Mol Biol Lett; 2019; 24():68. PubMed ID: 31844419
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of PD-L1 in Cervical Cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract][Full Text] [Related]
26. Improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression.
Liu LW; Yang MY; Zhou M; Li JJ; Liu B; Pan YY
Cancer Biomark; 2017 Dec; 20(4):609-615. PubMed ID: 28869441
[TBL] [Abstract][Full Text] [Related]
27. Genome-Wide Profiling of Human Papillomavirus DNA Integration into Human Genome and Its Influence on PD-L1 Expression in Chinese Uygur Cervical Cancer Women.
Yang-Chun F; Sen-Yu W; Yuan Z; Yan-Chun H
J Immunol Res; 2020; 2020():6284960. PubMed ID: 32411801
[TBL] [Abstract][Full Text] [Related]
28. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
29. [miR-143 inhibits cell proliferation through targeted regulating the expression of K-ras gene in HeLa cells].
Qin HX; Cui HK; Pan Y; Hu RL; Zhu LH; Wang SJ
Zhonghua Zhong Liu Za Zhi; 2016 Dec; 38(12):893-897. PubMed ID: 27998464
[No Abstract] [Full Text] [Related]
30. MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC.
Xie WB; Liang LH; Wu KG; Wang LX; He X; Song C; Wang YQ; Li YH
Cell Physiol Biochem; 2018; 46(2):654-663. PubMed ID: 29617683
[TBL] [Abstract][Full Text] [Related]
31. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer.
Dong P; Xiong Y; Yu J; Chen L; Tao T; Yi S; Hanley SJB; Yue J; Watari H; Sakuragi N
Oncogene; 2018 Sep; 37(39):5257-5268. PubMed ID: 29855617
[TBL] [Abstract][Full Text] [Related]
32. microRNA-383 suppresses the PI3K-AKT-MTOR signaling pathway to inhibit development of cervical cancer via down-regulating PARP2.
Teng P; Jiao Y; Hao M; Tang X
J Cell Biochem; 2018 Jul; 119(7):5243-5252. PubMed ID: 29236322
[TBL] [Abstract][Full Text] [Related]
33. MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway.
Feng S; Sun H; Zhu W
Clin Transl Oncol; 2021 Mar; 23(3):450-458. PubMed ID: 32654106
[TBL] [Abstract][Full Text] [Related]
34. MiR-1258 promotes the apoptosis of cervical cancer cells by regulating the E2F1/P53 signaling pathway.
Peng X; Zhang Y; Gao J; Cai C
Exp Mol Pathol; 2020 Jun; 114():104368. PubMed ID: 31917289
[TBL] [Abstract][Full Text] [Related]
35. p53/microRNA-374b/AKT1 regulates colorectal cancer cell apoptosis in response to DNA damage.
Gong H; Cao Y; Han G; Zhang Y; You Q; Wang Y; Pan Y
Int J Oncol; 2017 May; 50(5):1785-1791. PubMed ID: 28339062
[TBL] [Abstract][Full Text] [Related]
36. Mifepristone inhibited tumor progression by disrupting the stability of PD-L1 by miR-127-3p/VAMP2 in ovarian cancer.
Gu Y; Zhang Y; Liu J
Pak J Pharm Sci; 2022 Jan; 35(1(Special)):393-400. PubMed ID: 35236654
[TBL] [Abstract][Full Text] [Related]
37. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
38. MiR-195-3p inhibits cell proliferation in cervical cancer by targeting BCDIN3D.
Jin M; Wang L; Zheng T; Yu J; Sheng R; Zhu H
J Reprod Immunol; 2021 Feb; 143():103211. PubMed ID: 33157501
[TBL] [Abstract][Full Text] [Related]
39. MiR-200a promotes proliferation of cervical cancer cells by regulating HIF-1α/VEGF signaling pathway.
Su X; Lang C; Luan A; Zhao P
J BUON; 2020; 25(4):1935-1940. PubMed ID: 33099935
[TBL] [Abstract][Full Text] [Related]
40. Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.
Chen Z; Pang N; Du R; Zhu Y; Fan L; Cai D; Ding Y; Ding J
Mediators Inflamm; 2016; 2016():6891482. PubMed ID: 27721577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
